These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 752875)

  • 1. Malignant melanoma (stage 1): a clinical trial of adjuvant BCG immunotherapy.
    Paterson AH; Willans D; Jerry LM; McPherson TA
    Recent Results Cancer Res; 1978; 68():387-92. PubMed ID: 752875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant BCG immunotherapy for malignant melanoma.
    Paterson AH; Willans DJ; Jerry LM; Hanson J; McPherson TA
    Can Med Assoc J; 1984 Oct; 131(7):744-8. PubMed ID: 6383591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of BCG adjuvant immunotherapy for melanoma of the head and neck.
    Eilber FR; Townsend CM; Morton DL
    Am J Surg; 1976 Oct; 132(4):476-9. PubMed ID: 1015538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma.
    Tan JK; Ho VC
    J Dermatol Surg Oncol; 1993 Nov; 19(11):985-90. PubMed ID: 8245304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases.
    Morton DL; Eilber FR; Holmes EC; Ramming KP
    Aust N Z J Surg; 1978 Feb; 48(1):49-52. PubMed ID: 276348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
    Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
    N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH; Deutschmann EM; Schultheis W; Deicher H
    Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
    Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
    J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythema multiforme as a complication of BCG scarification technique.
    Tschen EH; Jessen RT; Robertson G; Becker LE
    Arch Dermatol; 1979 May; 115(5):614-5. PubMed ID: 443840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
    Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
    Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant immunotherapy of malignant melanoma.
    Aranha GV; McKhann CF; Grage TB; Gunnarsson A; Simmons RL
    Cancer; 1979 Apr; 43(4):1297-303. PubMed ID: 445331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
    Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCG immunotherapy in patients with malignant melanoma.
    Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
    Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined BCG and irradiation treatment of skin metastases originating from malignant melanoma.
    Plesnicar S; Rudolf Z
    Cancer; 1982 Sep; 50(6):1100-6. PubMed ID: 7104950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCG immunotherapy as a systemic adjunct to surgery in malignant melanoma.
    Morton DL; Eilber FR; Holmes EC; Sparks FC; Ramming K
    Med Clin North Am; 1976 May; 60(3):431-9. PubMed ID: 1271888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a nonrandomized trial in malignant melanoma patients (Clark's stages III--V) treated by post-surgical chemoimmunotherapy.
    Serrou B; Pujol H; Domas J; Gauci L
    Recent Results Cancer Res; 1978; 68():363-6. PubMed ID: 752871
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).
    Czarnetzki BM; Macher E; Suciu S; Thomas D; Steerenberg PA; Rümke P
    Eur J Cancer; 1993; 29A(9):1237-42. PubMed ID: 8343260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled study for prolonged chemotherapy, immunotherapy, and chemotherapy plus immunotherapy as an adjuvant to surgery in malignant melanoma (Trial 6): preliminary report.
    Veronesi U; Beretta G
    Recent Results Cancer Res; 1978; 68():375-9. PubMed ID: 752873
    [No Abstract]   [Full Text] [Related]  

  • 20. BCG immunotherapy in previously treated malignant melanoma patients.
    Mujagić H; Kolarić K; Malenica B; Nola P
    Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.